Skip to content
Home » News » TransCure bioServices involved in Targovax’s results

TransCure bioServices involved in Targovax’s results

    TransCure bioServices involved in Targovax's results

    Targovax published efficacy data using TransCure’s full human immune system hu-mouse models.

    Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors.

    In this paper, they demonstrate the “Synergistic effect of oncolytic virus combined with anti-PD-1 against Melanoma”

    TransCure’s humanized mice are the preferred in vivo models for combination therapy evaluation.

    Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model

    Lukasz Kuryk, Anne-Sophie W. Møller & Magnus Jaderberg


    Malignant melanoma is an aggressive type of skin cancer whose incidence is increasing globally. Although surgery is effective in early stage melanoma, patients with advanced melanoma only have a 20% 5-year survival rate. Hence, combinations of existing and new immunotherapy technologies and immunotherapeutic agents are being evaluated. ONCOS-102 is an oncolytic adenovirus armed with human GM-CSF and an Ad5/3 chimeric capsid. It has shown to be well tolerated in phase I study (NCT01598129) wherein it induced antitumor immunity, infiltration of CD8 + T cells to tumors, and upregulation of PD-L1. We propose that ONCOS-102 could serve as an immunosensitizer in combination therapies with checkpoint inhibitors.  In this preclinical study, we investigated the cytotoxicity of ONCOS102 and pembrolizumab, an anti-PD-1 antibody, in four human melanoma cell lines, A375, A2058, SKMel-2 and SK-Mel-28. Humanized mice engrafted with A2058 melanoma cells showed significant tumor volume reduction after ONCOS-102 treatment. Combination of pembrolizumab with ONCOS-102 reduced tumor volume to an even greater extent, while pembrolizumab (200 µg, or 400 µg) did not show any therapeutic benefit by itself. Body weight loss, and metastasis were not significantly affected by any treatment. These data support the scientific rationale for the ongoing clinical study of combination therapy of ONCOS-102 and pembrolizumab for the treatment of melanoma (NCT03003676).